Previous close | 91.25 |
Open | 91.25 |
Bid | 89.90 |
Ask | 94.50 |
Strike | 970.00 |
Expiry date | 2024-08-16 |
Day's range | 91.25 - 91.25 |
Contract range | N/A |
Volume | |
Open interest | 1 |
Eli Lilly and Company (NYSE: LLY) announced detailed results from the SURMOUNT-OSA phase 3 clinical trials evaluating tirzepatide injection (10 mg or 15 mg) for the treatment of moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity, with and without positive airway pressure (PAP) therapy. In both studies, tirzepatide achieved all primary and key secondary endpoints for both the efficacyi and treatment-regimenii estimands and demonstrated a mean reduction of up to 62.8% on the a
Zepbound and related products could generate more than $50 billion of sales in 2029. There is a lot more in Lilly’s pipeline.
Holding on to popular or trending stocks for the long-term can make your portfolio a winner.